Glioma is a type of tumor that occurs in the brain and spinal cord. Gliomas begin in the gluey supportive cells (glial cells) that surround nerve cells and help them function.
Substantial increase in number of patients suffering from chronic diseases and rise in mortality due to glioma are major factors expected to increase demand for enhanced diagnostic and treatment this is expected to drive the growth of global glioma diagnosis market. According to the National Brain Tumor Society, it is estimated that more than 10,000 individuals in the United States will succumb to glioblastoma every year. The five-year survival rate for glioblastoma patients is only 6.8 percent, and the average length of survival for glioblastoma patients is estimated to be only 12 to 18 months. Changing lifestyle pattern of consumers is impacting health. People exposed to a type of radiation called ionizing radiation have an increased risk of brain tumor this is increasing the risk of glioma. Availability of advanced infrastructure in developed countries is helping healthcare professionals to treat glioma. Their approach towards biopsy, MRI is gaining important in order to detect cancer and aid in treating the patients. Government is focused on delivering enhance solutions to patients. Collaborative approach among government and public players for R&D activities and on-time approvals for clinical trials is expected to impact the growth of glioma diagnosis market.
In 2020, FDA approved the investigational new drug application for Berubicin for the treatment of adult patients with glioblastoma to CNS Pharmaceuticals. The approval is expected to help the company to begin administering the drug or product to humans. This is expected to help the company to enhance the clinical trials and introduce novel solutions in the market.
In 2020, Plus Therapeutics, a global drug manufacturing company received FDA approval orphan drug designation to rhenium nanoliposomes for the treatment of patients with recurrent glioblastoma. The designation is expected to help the company to qualify for various incentives, including tax credits for qualified clinical trials and upon regulatory approval 7 years of market exclusivity. This is expected to help the company to enhance the business and increase the product portfolio.
Rise in number of geriatric population across the globe and growing brain tumor problems among old age people is expected to increase demand better, minimal invasive diagnostic procedures are expected to support the growth of target market. Factors such as high cost associated to diagnosis and surgery and lack of reimbursement policies are expected to hamper the growth of global glioma diagnosis market. In addition, lack of developed infrastructure in developing countries in order to adopt advanced devices is expected to challenge the growth of target market. However, increasing investment by major players for R&D activities and rising spending by the government for development of hospital infrastructure in order to deliver enhanced care are factors expected to create new opportunities for players operating in the glioma diagnosis market over the forecast period. In addition, players focus towards tracking the untapped market in developing countries is expected to support the revenue transaction of the target market.
Segment Analysis by Region
The market in North America is expected to account for major revenue share in the global glioma diagnosis market due to high patient pool suffering from cancer. According to National Brain Tumor Society, more than 13,000 Americans are expected to receive a GBM diagnosis in 2020. Availability of advanced infrastructure for R&D activities and presence of large number of players operating in the country are factors expected to support the growth of glioma diagnosis market
The market in Asia Pacific is expected to witness faster growth in the target market due to rising awareness among consumers. In addition, rise in healthcare spending and increasing partnership between public and private players for interdiction of novel drugs is expected to support the growth of target market.
The global glioma diagnosis market is highly competitive due to presence of large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition.
Glioma Diagnosis Market Segment Analysis, 2019
The global glioma diagnosis market is segmented into tumor type, grade, diagnosis test, and end use. The Tumor type segment is divided into primary tumors and secondary tumors. Among tumor type the primary tumor segment is expected to account for major revenue share in the global glioma diagnosis market. The end use segment is bifurcated into hospitals & clinics, diagnostic imaging centers, cancer research institutes, and others. The players profiled in the report are GE Healthcare, Siemens Healthineers, Koninklijke Philips N.V., Shimadzu Corporation, Hitachi Medical Corporation, Fujifilm Holdings Corporation, Carestream Health, Hologic, Inc., CANON MEDICAL SYSTEMS CORPORATION, and ESAOTE SPA.
Market By Tumor Type
Market By Grade
Recurrent high-grade gliomas
Market By Diagnostic Test
Computed Tomography (CT) scan
Magnetic Resonance Imaging (MRI)
Positron Emission Tomography (PET) scan
Market By End Use
Hospitals & Clinics
Diagnostic Imaging Centers
Cancer Research Institutes
Market By Geography
• Rest of Europe
• South Korea
• Rest of Asia-Pacific
• Rest of Latin America
Middle East & Africa
• South Africa
• Rest of Middle East & Africa
Substantial increase in number of patients suffering from chronic diseases and rise in mortality due to glioma are major factors expected to increase demand for enhanced diagnostic and treatment this is expected to drive the growth of global glioma diagnosis market.
In grade the low-grade gliomas segment is growing at faster pace.
In the global market the Asia Pacific region is expected to grow faster.
Some of the players considered in the report scope are GE Healthcare, Siemens Healthineers, Koninklijke Philips N.V., Shimadzu Corporation, and Hitachi Medical Corporation.
The North America is expected to account for major revenue share in the global market.
In end use the hospitals segment is growing at faster pace.
Factors such as high cost associated to diagnosis and surgery and lack of reimbursement policies are expected to hamper the growth of global glioma diagnosis market.